[Value of mistletoe lectin standardized mistletoe extract for evaluating antitumor properties].
It could be shown from several experiments that carbohydrate-binding mistletoe lectins represent the pharmacologically active constituents of mistletoe extracts. On the basis of these findings, it was possible to develop an extract preparation standardized with respect to the mistletoe lectin concentration. This drug is the first mistletoe preparation that fulfills the criteria of the guidelines for the development of drugs (1) regarding its quality and stability of the active ingredients under certain storage conditions. The quality of this preparation has also been shown in several animal models to demonstrate antitumoral potencies.
Mengs
U
U
Forschung und Entwicklung, Madaus AG, Köln, Deutschland. u.mengs@madaus.de
Witthohn
K
K
Schwarz
T
T
Lentzen
H
H
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D004355:Drug Stability; D004356:Drug Storage; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D028321:Plant Preparations; D010940:Plant Proteins; D012015:Reference Standards; D054790:Ribosome Inactivating Proteins, Type 2; D014118:Toxins, Biological / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000972:Antineoplastic Agents, Phytogenic; D028321:Plant Preparations; D010940:Plant Proteins; D054790:Ribosome Inactivating Proteins, Type 2; D014118:Toxins, Biological; C009674:ribosome inactivating protein, Viscum